• Reyon Pharmaceutical cut its planned convertible bond issuance to KRW 9 billion from KRW 10 billion in an October 27, 2026, correction.
• Shares issuable upon conversion fell to 884,955 from 983,284, with the conversion price unchanged at KRW 10,170.
• Operating funds earmarked for 2027 declined to KRW 4 billion from KRW 5 billion.
• The maximum call option amount decreased to KRW 1.8 billion from KRW 2 billion, retaining the 20% limit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Reyon Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261027000356), on October 27, 2026, and is solely responsible for the information contained therein.